PTCT on Nasdaq

PTC Therapeutics

Logo: PTC Therapeutics, Public domain, via Wikimedia Commons5

Pharmaceutical company

PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 19, 2026.

Overview

Jan 1, 1998Founded1

Compare with Sarepta Therapeutics, PHIBRO ANIMAL HEALTH CORP or Endo International plc, or pick any stock.

  • TickerPTCT on Nasdaq1
  • Industrypharmaceutical industry1
  • HeadquartersSouth Plainfield1
  • Websitewww.ptcbio.com
  • Legal formDelaware corporation1
  • Incorporated inDE6
  • Business address500 Warren Corporate Center Drive, Warren, Nj 070596
  • Filer categoryLarge accelerated filer6
  • LEI549300UJLWOIWFDGB3184
  • StatusActive4
  • LEI statusIssued and current4
  • Registered addressc/o CORPORATION SERVICE COMPANY, 251 LITTLE FALLS DRIVE, 19808 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 28782754

See how the biggest companies compare on our leaderboards

PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

50.1%Operating margin8
39.4%Net margin8
114.5%Revenue growth, 20258
$702.3MFree cash flow8

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Collaboration and License Revenue brought in 55% of the revenue PTC Therapeutics broke down this way in fiscal 2025.

  1. Collaboration and License Revenue$998.4M855%up 328307% from 2024
  2. Royalty$244.2M813%up 20% from 2024
  3. Translarna1(Member)$235.3M813%down 27% from 2024
  4. Emflaza$146.4M88%down 29% from 2024
  5. Sephience$111.2M86%
  6. Upstaza and Kebilidi$56.6M83%up 235% from 2024
  7. Other Products$37.3M82%up 1% from 2024
Products and services by year
Products and services202320242025
Collaboration and License Revenue$100.0M$304.0K$998.4M
Royalty$168.9M$203.9M$244.2M
Translarna1(Member)$332.8M$321.1M$235.3M
Emflaza$255.1M$207.2M$146.4M
Sephience$111.2M
Upstaza and Kebilidi$18.8M$16.9M$56.6M
Other Products$31.5M$36.9M$37.3M

Regions

United States brought in 31% of the revenue PTC Therapeutics broke down this way in fiscal 2025.

  1. United States$252.2M831%up 22% from 2024
  2. Rest of the world$235.9M829%down 40% from 2024
  3. All Other countries Other Than Russia, Brazil And united States$168.4M820%down 15% from 2024
  4. RU$100.4M812%down 5% from 2024
  5. Brazil$65.7M88%down 9% from 2024
Regions by year
Regions202320242025
United States$255.1M$207.2M$252.2M
Rest of the world$393.7M$235.9M
All Other countries Other Than Russia, Brazil And united States$238.5M$197.5M$168.4M
RU$86.0M$105.4M$100.4M
Brazil$58.6M$72.1M$65.7M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development26¢$455.2M
  • Selling, general and admin20¢$347.1M
  • Other costs13¢$231.6M
  • Income tax1¢$14.0M
  • Profit39¢$682.6M

Out of $1.7B in revenue.8

Where each dollar of operating cash went, fiscal 2025

  • Capital spending1¢$8.9M
  • Kept or used elsewhere99¢$702.3M

Out of $711.2M of cash from operations.8

Financial statements

Revenue91011128$1.7B in 2025+464% since 2019
0$500.0M$1.0B$1.5B$2.0B2019: $307.0M$307.0M20192020: $380.8M$380.8M2020+24%2021: $538.6M$538.6M2021+41%2022: $698.8M$698.8M2022+30%2023: $937.8M$937.8M2023+34%2024: $806.8M$806.8M2024−14%2025: $1.7B$1.7B2025+115%
Operating income91011128$866.9M in 2025
-$500.0M0$500.0M$1.0B2019: -$241.2M-$241.2M20192020: -$431.8M-$431.8M2020+79%2021: -$374.4M-$374.4M2021−13%2022: -$447.4M-$447.4M2022+19%2023: -$439.5M-$439.5M2023−2%2024: -$302.6M-$302.6M2024−31%2025: $866.9M$866.9M2025
Net income91011128$682.6M in 2025
-$1.0B-$500.0M0$500.0M$1.0B2019: -$251.6M-$251.6M20192020: -$438.2M-$438.2M2020+74%2021: -$523.9M-$523.9M2021+20%2022: -$559.0M-$559.0M2022+7%2023: -$626.6M-$626.6M2023+12%2024: -$363.3M-$363.3M2024−42%2025: $682.6M$682.6M2025

Every line of the income statement as filed: the last 3 fiscal years, latest first.8

Period ending2025-12-312024-12-312023-12-31
Total revenues$1.7B$806.8M$937.8M
Cost of product, collaboration and license sales, excluding amortization of acquired intangible assets$47.0M$57.4M$65.5M
Amortization of acquired intangible assets$24.7M$60.7M$222.6M
Research and development$455.2M$534.5M$666.6M
Selling, general and administrative$347.1M$300.9M$332.5M
Change in the fair value of contingent consideration-$800.0K-$4.5M-$127.7M
Intangible asset impairment$159.5M$217.8M
Tangible asset impairment and (gains) losses on transactions, net-$9.6M$750.0K
Total operating expenses$863.7M$1.1B$1.4B
Income (loss) from operations$866.9M-$302.6M-$439.5M
Interest expense, net-$152.2M-$167.0M-$129.2M
Other (expense) income, net-$18.1M$6.5M$10.1M
Gain on sale of priority review voucher$99.9M
Loss on extinguishment of debt-$137.6M
Income (loss) before income tax (expense) benefit$696.6M-$363.1M-$696.1M
Income tax (expense) benefit-$14.0M-$176.0K$69.5M
Net income (loss) attributable to common stockholders$682.6M-$363.3M-$626.6M
Basic (in shares)79.5M shares76.8M shares74.8M shares
Diluted (in shares)88.3M shares76.8M shares74.8M shares
Basic$8.58-$4.73-$8.37
Diluted$7.78-$4.73-$8.37

Compare PTC Therapeutics with another company

Leadership

Who has led PTC Therapeutics, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Stuart Walter Peltz2013–2023
  2. Eric Pauwels2024–2025

President

  1. Claudia De Oliveira Ribeiro Hirawat2013–2015

Chief financial officer

  1. Shane William Charles Kovacs2013–2017
  2. Emily Luisa Hill2019–2023
  3. Pierre Gravier2023–now

Chief operating officer

  1. Marcio Souza2017–2020
200020052010201520202025
Board members and other officers (29)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Dr. Klein is the Chief Executive Officer and the Director of the Development Committee of the Issuer.Matthew B. Klein, M.D. named May 8, 202350
  • Dr. Almstead is the Chief Technical Operations Officer of the Issuer.Neil B. Almstead, Ph.D named May 8, 202350
  • DirectorAllan D. Jacobson, Ph.D. named May 8, 202350
  • DirectorGlenn D. Steele Jr., M.D., Ph.D. named May 8, 202350
  • DirectorJerome B. Zeldis, M.D., Ph.D. named May 8, 202350
  • DirectorStepanie S. Okey named May 8, 202350

Products and brands

In 2017, PTC acquired Emflaza (deflazacort) from Marathon Pharmaceuticals. PTC also owns Translarna, (Ataluren) marketed for nonsense mutation Duchenne muscular dystrophy. Together, the two products generated revenues of 174 million dollars and 260 million dollars in 2017 and 2018 respectively.

PTC has the commercialization rights for WAYLIVRA (volanesorsen) in Latin America.

In 2018, PTC acquired Agilis Biotherapeutics and a gene therapy candidate, GT-AADC, with its compelling clinical data in treating aromatic L-amino acid decarboxylase (AADC) deficiency. AADC deficiency is a rare CNS disorder arising from reductions in the enzyme AADC that result from mutations in the dopa decarboxylase (DDC) gene. As of 2024, the AAV based treatment for AADC deficiency has been approved by the FDA and commercialized in the United States as Kebilidi. It is the first FDA-approved gene therapy treatment for AADC deficiency. This same product was granted EMA approval for use in the European Union under the name Upstaza.

From Wikipedia’s article on PTC Therapeutics, shared under CC BY-SA 4.0.7

Former names

  • PTC THERAPEUTICS INCJan 2, 2004 to Oct 12, 20056

Timeline

  1. Apr 19, 2024New chief executive Eric Pauwels becomes CEO16
  2. Jun 20, 2013Went public Listed on NASDAQ1
  3. Jun 19, 2013New chief executive Stuart Walter Peltz becomes CEO17
  4. Jan 1, 1998Founded Founded1

Filings

661 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 72 major events, 290 insider forms, 45 large holders, 1 private raises, 232 other. The latest 20:

  1. Oct 13, 20264 EDGAR
  2. Oct 9, 2026144 EDGAR
  3. Oct 9, 20264 EDGAR
  4. Oct 7, 2026144 EDGAR
  5. Oct 7, 20264 EDGAR
  6. Oct 6, 2026144 EDGAR
  7. Oct 5, 2026144 EDGAR
  8. Oct 2, 20264 EDGAR
  9. Sep 30, 2026144 EDGAR
  10. Sep 21, 20268-K EDGAR
  11. Sep 18, 20264 EDGAR
  12. Sep 11, 20264 EDGAR
  13. Sep 9, 2026144 EDGAR
  14. Aug 28, 20264 EDGAR
  15. Aug 28, 20268-K EDGAR
  16. Aug 25, 2026144/A EDGAR
  17. Aug 21, 20264 EDGAR
  18. Aug 19, 2026144 EDGAR
  19. Aug 19, 20264 EDGAR
  20. Aug 17, 2026144 EDGAR

The 661 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

256 open-market trades by officers, directors and large owners since October 2021: 1 buys and 255 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 17, 2026SCHMERTZLER MICHAELDirectorSale10,000$67.85$678.5KForm 4
Sep 16, 2026SCHMERTZLER MICHAELDirectorSale10,000$67.12$671.2KForm 4
Sep 10, 2026SCHMERTZLER MICHAELDirectorSale10,000$67.34$673.4KForm 4
Sep 9, 2026SCHMERTZLER MICHAELDirectorSale10,000$67.84$678.4KForm 4
Aug 27, 2026SCHMERTZLER MICHAELDirectorSale12,500$71.58$894.8KForm 4
Aug 26, 2026SCHMERTZLER MICHAELDirectorSale12,500$72.94$911.7KForm 4
Aug 20, 2026SCHMERTZLER MICHAELDirectorSale12,500$71.11$888.9KForm 4
Aug 19, 2026SCHMERTZLER MICHAELDirectorSale12,500$73.32$916.6KForm 4
Aug 17, 2026Boulding Mark ElliottEXEC. VP AND CLOSale2,813$72.57$204.1KForm 4
Aug 4, 2026Klein Matthew B.CHIEF EXECUTIVE OFFICERSale10,292$68.57$705.7KForm 4
Jul 14, 2026Gravier PierreCHIEF FINANCIAL OFFICERSale3,494$80.35$280.7KForm 4
Jul 9, 2026Smith Mary L.DirectorSale15,834$90.00$1.4MForm 4
Jul 9, 2026Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICERSale2,464$90.25$222.4KForm 4
Jul 7, 2026Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICERSale24,613$88.89$2.2MForm 4
Jul 6, 2026Boulding Mark ElliottEXEC. VP AND CLOSale5,079$85.08$432.1KForm 4
Jul 6, 2026Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICERSale22,161$86.00$1.9MForm 4
Jun 26, 2026Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICERSale8,130$85.26$693.2KForm 4
Jun 25, 2026Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICERSale20,960$85.97$1.8MForm 4
Jun 24, 2026Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICERSale5,323$85.03$452.6KForm 4
Jun 22, 2026Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICERSale23,749$80.90$1.9MForm 4

All 256 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Apr 10, 2023Raised $35.9 million in a private offering of equity Form D: 40 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.13,964,554$1.1B0.0%+1,015,837
Rtw Investments, LP7,746,415$631.9M5.4%No change
Jupiter Topco LLC7,236,402$590.2M0.2%New
Vanguard Portfolio Management LLC4,928,111$402.0M0.0%+123,517
State Street Corp4,598,952$375.1M0.0%+252,433
Wellington Management Group Llp4,128,273$336.7M0.1%+185,663
Vanguard Capital Management LLC3,739,127$305.0M0.0%+62,871
Geode Capital Management, LLC2,207,376$180.1M0.0%−2,578
Toronto Dominion Bank2,165,846$176.7M0.3%−860,117
Westfield Capital Management Co LP1,956,156$159.6M0.5%New
Hood River Capital Management LLC1,738,613$141.8M1.0%+74,054
William Blair Investment Management, LLC1,722,688$140.5M0.4%New
D. E. Shaw & Co., Inc.1,548,919$126.3M0.1%−91,462
Tang Capital Management LLC1,500,000$122.4M5.6%No change
Bank Of America Corp /de/1,452,277$118.5M0.0%−434,564
Driehaus Capital Management LLC1,440,107$117.5M0.7%+424,335
Fmr LLC1,398,261$114.1M0.0%−130,101
Jefferies Financial Group Inc.1,357,042$110.7M1.0%+2,583
Fuller & Thaler Asset Management, Inc.1,156,819$94.4M0.3%New
Pictet Asset Management Holding SA1,147,844$93.6M0.1%−35,876
Morgan Stanley1,103,675$90.0M0.0%+429,541
Armistice Capital, LLC1,071,395$87.4M2.4%−1,003,054
Blue Sparrow, LLC /DE1,050,700$85.7M0.8%+860,100
Franklin Resources Inc1,027,327$83.8M0.0%−94,061
Invesco Ltd.941,581$76.8M0.0%+76,130

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63